Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Doggrell
Sheila A
SA
School of Science, Charles Darwin University, PO Box 41246, Casuarina, NT 0811, Australia. s_doggrell@yahoo.com
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000284:Administration, Oral; D000631:Aminopyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000201:enzymology; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003521:Cyclopropanes / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000201:enzymology; D012123:Pulmonary Ventilation / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic
D000631:Aminopyridines; D000893:Anti-Inflammatory Agents; D001549:Benzamides; D003521:Cyclopropanes; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4